Related Experiment Videos
Renal side-effects of cyclosporin A with special reference to autoimmune diseases
M J Mihatsch1, G Thiel, B Ryffel
1Department of Pathology, University of Basle, Switzerland.
Abstract:
At therapeutic drug levels, the functional changes which occur are a reduction of glomerular filtration rate and renal plasma flow. At higher doses, morphological changes develop which may result, particularly in severe cases, in acute or chronic renal failure. The threshold for the development of irreversible vascular-interstitial lesions mainly depends on the increment of serum creatinine, age and drug dosage or drug blood level. Based on the experience with cyclosporin A (CyA), the following recommendations have been made for its clinical use, especially in patients with autoimmune diseases. The initial dose should not exceed 5 mg/kg body weight and the dose should be reduced if blood CyA levels are over 250 ng/ml; in addition, a dose reduction is recommended if serum creatinine values exceed 30% of pre-treatment values or if other signs of CyA toxicity, such as hepatotoxicity or hypertension, are found. Strict adherence to these suggestions should allow treatment of patients for prolonged periods without irreversible morphological lesions.
Insights
Cyclosporin A (CyA) can cause kidney damage, including reduced filtration and potential renal failure at higher doses. Clinical guidelines recommend dose adjustments based on blood levels and serum creatinine to prevent irreversible kidney lesions.
Area of Science:
- Nephrology
- Pharmacology
- Immunosuppression
Background:
- Cyclosporin A (CyA) is an immunosuppressive drug used in autoimmune diseases.
- Therapeutic drug levels of CyA can functionally impair the kidneys.
- Higher doses may lead to morphological changes and renal failure.
Purpose of the Study:
- To define the threshold for irreversible kidney damage from CyA.
- To provide clinical recommendations for safe CyA use.
- To minimize nephrotoxicity in patients, particularly those with autoimmune conditions.
Main Methods:
- Analysis of functional and morphological changes in the kidney related to CyA dosage.
- Correlation of serum creatinine levels, age, and drug blood levels with lesion development.
- Review of clinical experience with CyA in patients with autoimmune diseases.
Main Results:
- Functional changes include reduced glomerular filtration rate and renal plasma flow.
- Irreversible vascular-interstitial lesions depend on serum creatinine increase, age, and CyA dose/blood level.
- Specific recommendations for initial dose (≤5 mg/kg) and dose reduction criteria (blood levels >250 ng/ml, creatinine increase >30%, or other toxicities) were established.
Conclusions:
- Adherence to recommended dosage and monitoring can prevent irreversible kidney damage.
- Safe long-term treatment with CyA is achievable with careful management.
- Clinical guidelines aim to balance therapeutic efficacy with minimizing nephrotoxicity.